Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lifecell (LIFC) -- Ignore unavailable to you. Want to Upgrade?

To: slowy@lowys.com who wrote (353)	5/2/1999 3:57:00 PM
From: W Shakespeare	Read Replies (1) \| Respond to of 395

Hello to the LIFC thread. I am considering an investment in LIFC but have a few issues that need some input. First, I am concerned that the company receives the raw supply for its main product from donations. The company has no way to regulate or insure its supplies. Also, from reading the 10-K, the pricing of donated skin could fall under several regulations. Second, I am confused about the exact status of Alloderm in relation to the FDA. Is the issue settled or could the FDA suddenly decide that Alloderm does not fall under the exception it currently holds. Finally, the few analysts following the stock seem to have cut their earnings estimates and price targets severely over the last year. Even the current estimates for the stock seem overly optimistic (one uses an assumed sales growth rate of 95%). Is LIFC close to profitability or does it have a few more years of losses before it turns the corner? Turning profitable is what will bring this stock out of its current trading range. Thank you in advance for your assistance.